Crohn’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Crohn’s Disease (US)

Children with Crohn’s disease (CD) have a more-complicated disease course than that of adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and then progress to more-potent drugs, such as biologics and/or immunosuppressants. This scenario has changed, and more physicians are now prescribing biologics, especially tumor necrosis factor (TNF)-alpha inhibitors (e.g., infliximab, adalimumab), as first-line therapy for both newly diagnosed and recently treated pediatric CD patients. Non-TNF biologics, including Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara, and oral targeted therapies such as AbbVie’s Rinvoq, may be prescribed as well, particularly after anti-TNF failure.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric CD patients?
• How have Entyvio and Rinvoq been integrated into the treatment algorithm, and what is their source of business?
• What percentage of pediatric CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of pediatric CD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Markets covered: United States

Key drugs: Entyvio, Stelara, Rinvoq, Remicade and infliximab biosimilars, Humira and adalimumab biosimilars, Skyrizi